Mather Group LLC. Boosts Holdings in Hologic, Inc. (NASDAQ:HOLX)

Mather Group LLC. increased its position in Hologic, Inc. (NASDAQ:HOLX) by 236.0% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,937 shares of the medical equipment provider’s stock after buying an additional 2,063 shares during the quarter. Mather Group LLC.’s holdings in Hologic were worth $212,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. FMR LLC lifted its holdings in Hologic by 64.0% in the 3rd quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares in the last quarter. Swedbank AB boosted its holdings in Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock valued at $157,788,000 after purchasing an additional 306,562 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Hologic by 21.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock valued at $110,700,000 after purchasing an additional 238,222 shares in the last quarter. Finally, Barclays PLC increased its holdings in Hologic by 47.6% during the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after purchasing an additional 231,578 shares during the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Wall Street Analysts Forecast Growth

HOLX has been the subject of several research analyst reports. William Blair reiterated an “outperform” rating on shares of Hologic in a research note on Thursday. Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $80.00 to $75.00 in a report on Thursday. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research report on Thursday, November 14th. Morgan Stanley reduced their price target on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Finally, JPMorgan Chase & Co. boosted their price objective on Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Nine analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Hologic currently has an average rating of “Moderate Buy” and an average price target of $85.77.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $65.45 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The firm has a market capitalization of $14.77 billion, a PE ratio of 19.65, a P/E/G ratio of 2.35 and a beta of 0.97. Hologic, Inc. has a 1-year low of $64.87 and a 1-year high of $84.67. The business’s fifty day moving average price is $72.63 and its two-hundred day moving average price is $77.86.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. On average, research analysts expect that Hologic, Inc. will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.